Photo: Courtesy of Celgene (https://www.celgene.com/media-library/celgene-logo-with-tagline-no-background/)
Biopharmaceutical company Celgene and India-based rival Natco Pharma have settled a lawsuit centring on the alleged infringement of a number patents covering the Revlimid (lenalidomide) drug.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Celgene; Natco Pharma; Revlimid; cancer